| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a09ca043d7e596facff1f44b746e2f4d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02 |
| filingDate |
2009-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_980c67f056e9e774d9f05b6d0633e154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b184c77661a9fc10522cc5b3d054ec31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df13f04c2368eaf15ac131cd08e3730c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b866873a51c2e40e1e61933f9b0a23fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d42ccaf0956927b75c19cf0ac68a3fff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c93e5e82a15f7f9478d5ba583c1ee824
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_976968b3892398ae9e9cdb1a60268e19 |
| publicationDate |
2016-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2283849-B1 |
| titleOfInvention |
A2 botulinum neurotoxin for use in the treatment of muscle overactivity in the presence of type a1 neutralising antibodies |
| priorityDate |
2008-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |